TIDES Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Biotech companies at TIDES Europe 2026

Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website

35 biotech companies are at TIDES Europe 2026 — 42 presentations on the program and 2 with a booth in the exhibit hall. Most represented: Alnylam Pharmaceuticals (2 on the program), Constructive Bio (2 on the program), Ionis Pharmaceuticals (2 on the program). 10 of them have their own page in this guide. As of Nov 2, 2026.

All 167 organizations at TIDES Europe 2026 →

Focus
Top represented
Showing 1–17 of 35 organizations
OrganizationTIDES Europe 2026 Attendance
Biotech
Develops and markets RNA interference (RNAi) therapeutics, including GalNAc-conjugated siRNA medicines for genetic, cardiometabolic and other diseases.
Talk
Thu Nov 5
15:00–15:30
Genetically Validated Targets and the Next Wave of RNAi Therapeutics: Progress from the Alnylam Pipeline
Progress in gene-silencing medicines at one company, including how human genetics points to new targets and what a broad pipeline has taught them.
Talk
Thu Nov 5
10:45–11:25
Part 1: siRELIS: A Convergent Enzymatic Ligation Strategy for siRNA Manufacturing; Part 2: Enzyme Development for Oligonucleotide Therapeutics Manufacturing
Using engineered joining enzymes to assemble siRNA from short building blocks, and what scaling that approach taught two companies.
with Almac
CB
Constructive Bio
Cambridge, United Kingdom
Biotech
Develops genetic code expansion technology to make proteins and peptides containing non-standard amino acids.
Talk
Fri Nov 6
09:10–10:00
Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape
What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for.
Post-event symposium · with Cantoni Therapeutics, Novo Nordisk, Aphaia Pharma
Talk
Fri Nov 6
13:20–13:40
Presentation: Engineering Advanced GLP-1 Peptides Through Targeted Site-Specific Modifications
Post-event symposium: Technology and Process Innovation Spotlight
Biotech
Develops and markets antisense oligonucleotide medicines for neurological, cardiometabolic and rare diseases.
Talk
Wed Nov 4
08:35–09:05
Regulatory CMC Strategies and Health Authority Interactions for Oligonucleotide Programs
How manufacturing and quality filings for antisense drugs differ between the US and other regions, drawn from recent commercial applications.
Talk
Thu Nov 5
08:35–09:05
Moving Towards a Greener SPOS Process
Practical ways to cut the environmental cost of oligonucleotide synthesis, including smaller wash volumes, new column designs and recycled solvent.
Wave Life Sciences
Cambridge, Massachusetts
Biotech
Develops stereopure oligonucleotide medicines, including siRNA, antisense and RNA editing candidates.
Talk
Wed Nov 4
09:05–09:35
Applying Small Molecule Drug Design Principles to Improve the Drug-like Properties of siRNA
Designing siRNA the way chemists design small-molecule drugs, controlling each linkage to get lasting gene silencing in mouse liver and kidney.
Talk
Thu Nov 5
16:30–17:00
Synthesis and Characterization of Stereopure Chimeric Oligonucleotides
Making and testing oligonucleotides in which every backbone link has one fixed mirror-image form, in small batches, to link structure to activity.
Zealand Pharma
Søborg, Denmark
Biotech
Danish biotech developing peptide medicines for obesity and metabolic diseases, including amylin and GLP-1 analogues.
Talk
Wed Nov 4
16:15–16:45
Dapiglutide: From Lab to Large Scale Manufacture through Innovative Peptide Process Development
How process changes in making the peptide drug dapiglutide raised its overall yield from about 20% to over 60%.
with Bachem
Talk
Fri Nov 6
10:30–10:55
Presentation: Exploring A Selective Amylin Receptor Agonist for Metabolic Disease
Post-event symposium: Clinical & Translational Updates
P
Priavoid
Biotech
Develops D-enantiomeric peptide drugs that break up toxic protein aggregates in neurodegenerative diseases, including Alzheimer's disease.
Talk
Thu Nov 5
15:00–15:30
Targeting Neurodegenerative Diseases with Priavoid’s Peptide Drug Development Platform
Peptides built from mirror-image amino acids that untangle protein clumps in Alzheimer's and Parkinson's, reaching the brain in mice after oral dosing.
Biotech
Develops oral treatments for obesity and metabolic disease, including a beaded glucose formulation that activates enteroendocrine cells.
Talk
Fri Nov 6
09:10–10:00
Keynote Panel: From Lab to Launch - Navigating the European Obesity Therapeutics Landscape
What it takes to turn obesity research into a product Europe will approve, manufacture at scale and actually pay for.
Post-event symposium · with Cantoni Therapeutics, Novo Nordisk, Constructive Bio
Talk
Fri Nov 6
14:00–14:20
Presentation: Enteroendocrine Cell Activation via Beaded Oral Glucose: A Multi-Hormonal Approach to Metabolic Regulation
Post-event symposium: Technology and Process Innovation Spotlight
NT
noctuRNA Therapeutics
Barcelona, Spain
Biotech
Pompeu Fabra University spin-off developing circular RNA therapeutics for infectious, neuromuscular and neurodegenerative diseases.
Chair
Wed Nov 4
13:55–14:00
Chairman’s Remarks: Emerging RNA and OIigonucleotide Modalities
Oligonucleotide Discovery, Preclinical and Clinical
Talk
Wed Nov 4
16:45–17:15
Novel Circular RNA Therapeutics for Infectious and Non-infectious Diseases
Engineered circular RNA that grabs onto folded, disease-causing RNA, tested in amyotrophic lateral sclerosis, myotonic dystrophy and viral infection.
Silence Therapeutics
London, United Kingdom
Biotech
Develops siRNA medicines using its mRNAi GOLD platform for cardiovascular, haematological and other diseases.
Talk
Wed Nov 4
10:15–10:45
Elongating siRNA Duration of Action by Enhanced Nuclease Resistance: End Stabilization Revisited
A modification near each end of a siRNA made gene silencing in mice last longer while needing fewer sulfur linkages.
Talk
Fri Nov 6
11:15–11:40
Presentation: Genetically-Validated INHBE Silencing with SLN098 siRNA for Enhanced Fat Loss and Lean Mass Preservation
Post-event symposium: Clinical & Translational Updates
OmniAb
Emeryville, California
BiotechExhibitor
Licenses antibody discovery platforms built on transgenic animals to drug developers.
Booth
Exhibiting at Booth K9
Tue, Nov 33:00pm–6:30pmWed, Nov 49:35am–4:15pmThu, Nov 59:35am–4:00pm
Talk
Wed Nov 4
09:55–10:05
OmniUltra™: A Dual Modality In Vivo Discovery Platform for Novel Human Antibodies and Structured Peptides
How antibodies carrying unusually long loops can reach deep pockets on a target, and how those loops work alone as small peptides.
PeptidesDiscovery & Clinical
A
Affilogic
Nantes, France
Biotech
Develops Nanofitins, small engineered protein scaffolds used as targeting ligands and therapeutics, including for organ-specific oligonucleotide delivery.
Talk
Thu Nov 5
08:05–08:35
Organ Specific Delivery of Oligonucleotides Using Nanofitins
How small engineered proteins attached to siRNA carried it into brain and heart muscle in animals and switched off a target gene.
Aicuris
Wuppertal, Germany
Biotech
Develops antiviral medicines for people with weakened immune systems and is now part of Asahi Kasei Therapeutics.
Talk
Wed Nov 4
11:15–11:45
AIC468, A First-in-class Antisense Oligonucleotide Targeting BKV in Kidney Transplant Patients
Animal and early trial safety data on an antisense drug against a virus that can destroy a transplanted kidney.
A
AIRNA
Cambridge, MA
Biotech
Develops RNA editing medicines, including a GalNAc-conjugated RNA base editing treatment for alpha-1 antitrypsin deficiency.
Talk
Wed Nov 4
10:45–11:15
AIR-001: A Highly Potent and Precise GalNAc-conjugated RNA Base Editing Treatment for Alpha-1 Antitrypsin Deficiency
Animal results and first-trial progress for an oligonucleotide that corrects the mutation causing alpha-1 antitrypsin deficiency, which damages lung and liver.
AT
Altamira Therapeutics
Biotech
Develops xPhore and related peptide-based platforms for delivering therapeutic nucleic acids such as siRNA and mRNA.
Talk
Thu Nov 5
11:15–11:45
xPhore: A Platform for DeLivering Therapeutic Nucleic Acids
A peptide that wraps around nucleic acid cargo to form nanoparticles aimed at tumours and inflamed tissue rather than the liver.
Biotech
Develops the synthetic antimicrobial peptidomimetic voxvoganan as an active ingredient for antimicrobial medical device coatings.
Talk
Thu Nov 5
14:00–14:30
Voxvoganan - A First in Class Mimetic of Antimicrobial Peptides
A three-amino-acid mimic of natural antibacterial peptides, how it was designed, and how it is made at industrial scale.
Avidity Biosciences
San Diego, CA
Biotech
Develops antibody oligonucleotide conjugates (AOCs) that deliver RNA therapeutics to muscle for neuromuscular diseases.
Panel
Thu Nov 5
10:15–10:45
From Small-Scale Knowledge to Commercial-Scale Manufacturing: Using Control Strategy to Justify Scale-up
How proving which process settings truly matter lets a small-scale recipe justify making the same oligonucleotide at commercial scale.
Bicycle Therapeutics
Cambridge, United Kingdom
Biotech
Develops bicyclic peptide therapeutics, including toxin and radionuclide conjugates, for cancer and other diseases.
Talk
Thu Nov 5
14:30–15:00
Bicyclic Peptide Technology: Pioneering Next-Generation Precision-Guided Therapeutics
How small looped peptides can act as carriers, clipping on drug payloads, radioactive atoms or oligonucleotides to reach tumours, muscle and brain.

Explore the full TIDES Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Amsterdam. Leave your work email and we’ll be in touch.

Privacy

Download the full TIDES Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from biotech companies

Tell us what you sell and we’ll find the people at these biotech companies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Browse TIDES Europe 2026 by

Exhibit hall

Not affiliated with or endorsed by TIDES Europe or its organizers. Submit a correction